Μεταβλητότητα γλυκόζης και καρδιά

Transcription

1 Μεταβλητότητα γλυκόζης και καρδιά Nίκη Κατσίκη MSc, PhD, MD, FRSPH IASO/EASO Scope Member EASD Diabetes & Cardiovascular Disease Group Member Μέλος ΔΣ της Ελληνικής Εταιρείας Αθηροσκλήρωσης Ειδική Παθολόγος, Ακαδημαϊκή Υπότροφος Α.Π.Θ. Υπεύθυνη ιατρείου παχυσαρκίας και λιπιδίων Τμήμα Ενδοκρινολογίας, Διαβήτη και Μεταβολισμού Α Παθολογική Κλινική, Νοσοκομείο ΑΧΕΠΑ, Θεσσαλονίκη

2 Δήλωση συμφερόντων Associate Editor of Angiology Associate Editor of Clinical Lipidology Associate Editor of the Hellenic College of Treatment of Atherosclerosis for The Open Cardiovascular Medicine Journal Section Editor of Archives of Medical Science Book Review and News and Views Editor of Current Vascular Pharmacology Editorial Board Member of Metabolism Clinical and Experimental and Current Medical Research and Opinion NK has given talks, attended conferences and participated in trials sponsored by Amgen, Angelini, Astra Zeneca, Boehringer Ingelheim, Galenica, MSD, Novartis, Novo Nordisk, Sanofi and WinMedica

3

4

5

6

7

8

9

10

11 DEVOTE 2: Day-to-day fasting glycemic variability and association with outcomes DEVOTE 2 was a prespecified secondary analysis of DEVOTE Associations of day-to-day fasting glycemic variability (based on the standard deviation of the pre-breakfast SMBG measurements) with severe hypoglycemia and outcomes were analyzed The effect of glycemic variability on outcomes was the same for Gla-100 and Deg-100 and data were pooled Day-to-day fasting glycemic variability was significantly associated with severe hypoglycemia and all-cause mortality The association between glycemic variability and MACE was not maintained after adjusting for baseline characteristics and the most recent HbA 1c Variability was reported on a continuous scale. Adjusted for HbA1c: most recent HbA1c on a continuous scale. Adjusted for HbA1c and BC: most recent HbA1c on a continuous scale and BC (investigational product, sex, region, age at baseline, smoking status at baseline, diabetes duration at baseline, CV risk-group inclusion criteria, insulin-naïve at baseline and renal function [egfr] at baseline). BC, baseline characteristics; SMBG, self-measured blood glucose. Zinman B et al. Diabetologia Sep 15. doi: /s z. [Epub ahead of print]

12

13

14

15 Diabetes Care 2018 Aug; dc

16

17

18

19

20

21

22 Br J Diabetes 2016;16(Suppl1):S3-S6

23 August 13, 2018 DOI:

24

25

26

27

28

29

30

31

32 Katsiki N, Triposkiadis F. Resistance to Diuretics in Heart Failure: Any Role for Empagliflozin? Curr Vasc Pharmacol Aug 31. [Epub ahead of print] Yaribeygi H, Butler AE, Atkin SL, Katsiki N, Sahebkar A. Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways. J Cell Physiol Aug 4. [Epub ahead of print] Mamakou V, Eleftheriadou I, Katsiki N, Makrilakis K, Tsioufis K, Tentolouris N. Antidiabetic Drugs as Antihypertensives: New Data on the Horizon. Curr Vasc Pharmacol. 2017;16(1): Athyros VG, Katsiki N, Karagiannis A. Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes? Curr Vasc Pharmacol. 2016;14(6): Katsiki N, Athyros VG, Mikhailidis DP. Cardiovascular effects of sodium-glucose cotransporter 2 inhibitors: multiple actions. Curr Med Res Opin. 2016;32(9): Katsiki N, Papanas N, Mikhailidis DP. Dapagliflozin: more than just another oral glucose-lowering agent? Expert Opin Investig Drugs. 2010;19(12):1581-9

33 Athyros VG, Katsiki N, Tentolouris N. Editorial: Do Some Glucagon-Like-Peptide-1 Receptor Agonists (GLP-1 RA) Reduce Macrovascular Complications of Type 2 Diabetes Mellitus A Commentary on the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) Trial. Curr Vasc Pharmacol. 2016;14(5): Athyros VG, Katsiki N, Karagiannis A. Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes? Curr Vasc Pharmacol. 2016;14(6): Athyros VG, Katsiki N, Mikhailidis DP. Editorial: Resolution of Non-Alcoholic-Steatohepatitis. More than One Drug Needed? Curr Vasc Pharmacol. 2016;14(4): Katsiki N, Christou GA, Kiortsis DN. Liraglutide and Cardiometabolic Effects: More than Just Another Antiobesity Drug? Curr Vasc Pharmacol. 2016;14(1):76-9. Karras S, Goulis DG, Mintziori G, Katsiki N, Tzotzas T. The effects of incretins on energy homeostasis: physiology and implications for the treatment of type 2 diabetes mellitus and obesity. Curr Vasc Pharmacol. 2012;10(6):

34

35

36

37

38

39

40

41 Guerci B, Monnier L, Serusclat P, Petit C, Valensi P, Huet D, Raccah D, Colette C, Quéré S, Dejager S. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study. Diabetes Metab. 2012;38(4): Kim HS, Shin JA, Lee SH, Kim ES, Cho JH, Son HY, Yoon KH. A comparative study of the effects of a dipeptidyl peptidase-iv inhibitor and sulfonylurea on glucose variability in patients with type 2 diabetes with inadequate glycemic control on metformin. Diabetes Technol Ther. 2013;15(10): (sitagliptin) González-Heredia T, Hernández-Corona DM, González-Ortiz M, Martínez-Abundis E. Effect of Linagliptin Versus Metformin on Glycemic Variability in Patients with Impaired Glucose Tolerance. Diabetes Technol Ther. 2017;19(8):

42 Παίζει ρόλο η διακύμανση της γλυκόζης στον καρδιαγγειακό κίνδυνο;

43 Στην κλινική πράξη (κατευθυντήριες οδηγίες);

44

45

46 Ευχαριστώ πολύ για την προσοχή σας!